Triumeq
Abacavir, Dolutegravir, Lamivudine
600/50/300mg
Indicated for HIV infection to support viral suppression.
HIV (Human Immunodeficiency Virus) targets CD4 immune cells, gradually weakening the body’s defences if left untreated. With modern antiretroviral therapy (ART), HIV is a manageable chronic condition rather than a fatal one. People on effective treatment achieve undetectable viral loads, stay well, and cannot transmit the virus sexually.
Abacavir, Dolutegravir, Lamivudine
600/50/300mg
Indicated for HIV infection to support viral suppression.
300/200mg
Intended to relieve viral replication in human immunodeficiency virus infection to support immune stability.
600 · 800mg
Developed to target human immunodeficiency virus infection to support immune system health.
After initial infection, many people experience a short flu-like illness (fever, swollen glands, sore throat) that resolves on its own. The virus then enters a long silent phase during which CD4 counts slowly fall. Without treatment, this eventually leads to AIDS, a stage defined by severe immune suppression and opportunistic infections. In Asia, HIV remains significant in South and Southeast Asia, with India, Indonesia, Thailand, and the Philippines among countries with the largest burdens.
ART combines medicines from different drug classes to suppress the virus below detectable levels. Common backbone agents include lamivudine, abacavir, and zidovudine, paired with integrase inhibitors such as dolutegravir or raltegravir, or the non-nucleoside agent efavirenz. Treatment is lifelong; stopping allows the virus to rebound. The full range of available regimens is listed in the HIV management category, which sits within the broader antivirals section.
Sudden severe headache, stiff neck, confusion, difficulty breathing, or unexplained rapid weight loss in someone with HIV warrant same-day medical attention, as these can signal opportunistic infections that need prompt treatment.